LINC02249 as A Potential Drug Target for Various Diseases (G26082)

Target Name: LINC02249

NCBI ID: G26082

LINC02249

Other Name(s): DKFZP434L187 | Long intergenic non-protein coding RNA 2249 | long intergenic non-protein coding RNA 2249

LINC02249 as A Potential Drug Target for Various Diseases

LINC02249 (DKFZP434L187) is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a member of the LINC (long non-coding RNA) family of proteins, which have been implicated in a wide range of cellular processes, including gene regulation, RNA metabolism, and cellular signaling.

Recent studies have identified LINC02249 as a potential drug target (or biomarker) for a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease. Its potential as a drug target is based on several factors, including its well-established role in various cellular processes, its expression in a variety of tissues, and its potential to interact with other proteins that are known to be targets for drugs.

One of the key mechanisms by which LINC02249 is thought to work as a drug target is its role in the regulation of cellular signaling pathways. LINC02249 has been shown to play a role in the regulation of several signaling pathways, including the TGF-β pathway, the Wnt pathway, and the Notch pathway. These pathways are involved in a wide range of cellular processes, including cell growth, differentiation, and survival, and are known to be targets for a variety of drugs, including those that are used to treat cancer, neurodegenerative diseases, and cardiovascular disease.

In addition to its role in cellular signaling pathways, LINC02249 is also thought to be involved in the regulation of gene expression. Several studies have shown that LINC02249 can interact with other proteins that are involved in gene expression, including the transcription factor Myb. These interactions may help to regulate the expression of target genes, including genes that are involved in cancer, neurodegenerative diseases, and cardiovascular disease.

Another potential mechanism by which LINC02249 could be used as a drug target is its role in the regulation of cellular apoptosis (programmed cell death). LINC02249 has been shown to play a role in the regulation of apoptosis in various tissues, including the brain. This suggests that it may be involved in the development and progression of some forms of cancer, including brain cancer.

In addition to its potential role in cellular signaling pathways and apoptosis, LINC02249 is also thought to be involved in the regulation of cellular adhesion and migration. Several studies have shown that LINC02249 can interact with other proteins that are involved in cellular adhesion and migration, including the protein vimentin. These interactions may help to regulate the movement of cells along the surface of various tissues and organs, including the brain and the heart.

Overall, LINC02249 is a protein that is well-established in various cellular processes and is thought to be involved in the regulation of a wide range of cellular processes, including signaling pathways, gene expression, apoptosis, and cellular adhesion and migration. Its potential as a drug target makes it an attractive target for researchers to investigate and develop new treatments for a variety of diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 2249

The "LINC02249 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02249 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets